COVID-19 vaccine maker Novavax swings to profit as sales climb

Novavax Inc. NVAX shares are up on Thursday following the company’s announcement of its fourth-quarter and full-year 2025 ...

Novavax posts Q4 revenue beat and net income for 2025

Novavax (NVAX) stock jumps as the company beats with its Q4 2025 revenue and records full-year profitability. Read more here.

Novavax raises revenue forecast on boost from vaccine deals; shares soar

By Mariam Sunny and Michael Erman Feb 26 (Reuters) - Novavax raised its adjusted revenue forecast for 2026 on Thursday, ...
Nasdaq

Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.

Nuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season "With today's approval, we will work with our partner Sanofi to provide ...
WTVD

Novavax says COVID-19 vaccine shows 90.4% overall efficacy in US Phase 3 trial

NEW YORK -- The American biotechnology company Novavax announced on Monday that its coronavirus vaccine candidate was found to have an overall efficacy of 90.4% in a Phase 3 trial conducted across the ...
FOX 5 Atlanta

Novavax delays timeline for COVID-19 vaccine regulatory clearance, production of shots

Novavax Inc. said this week that its COVID-19 vaccine would not receive regulatory clearance in the U.S. or the U.K. until at least July, while a shortage of materials has delayed its production ...
WTKR

Biden administration orders millions of Novavax COVID-19 vaccine doses

The Biden administration announced Monday that it would purchase 3.2 million doses of the Novavax COVID-19 vaccine. It will be offered at no cost to states and federal partners. “We remain committed ...
lex18

FDA authorizes Novavax's protein-based COVID-19 vaccine

The Food and Drug Administration (FDA) signed off Wednesday on an emergency use authorization for the Novavax COVID-19 vaccine for individuals 18 years of age and older. The Novavax vaccine is protein ...